IP Library › Granted Patent US 12,570,707
Granted Patent B2
US 12,570,707 · App. 17/415,852 · Granted Mar 10, 2026

Codon-optimised complement factor I

Inventor: Josephine Heather Lucienne Joel (Stevenage, GB)
Assignee: NOVARTIS PHARMACEUTICALS UK LIMITED
C07K14/472A61K48/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,570,707
App. No.
17/415,852
Granted
Mar 10, 2026
Kind
B2
Abstract

An isolated polynucleotide comprising a nucleotide sequence encoding a codon-optimised Complement Factor I (CFI).

Claims (6)

1 . An AAV vector particle comprising AAV2 capsid proteins and a polynucleotide comprising a nucleotide sequence encoding Complement Factor H-like Protein 1 (FHL1) and having at least 95% sequence identity to SEQ ID NO: 12 over the entire length of SEQ ID NO:12.

2 . The AAV vector particle of claim 1 , wherein the nucleotide sequence encoding FHL1 comprises the nucleotide sequence set forth in SEQ ID NO: 12.

3 . The AAV vector particle of claim 1 , wherein the nucleotide sequence encoding FHL1 is operably linked to a CMV promoter; a WPRE regulatory element; and/or a poly-A signal.

4 . An ex vivo cell transduced with the AAV vector particle of claim 1 .

5 . A pharmaceutical composition comprising the AAV vector particle of claim 1 in combination with a pharmaceutically acceptable carrier, diluent or excipient.

6 . The AAV vector particle of claim 3 , wherein the nucleotide sequence encoding FHL1 has at least 98% sequence identity to SEQ ID NO: 12 over the entire length of SEQ ID NO: 12.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2026
From: GYROSCOPE THERAPEUTICS LIMITED
To: NOVARTIS PHARMACEUTICALS UK LIMITED
Reel/Frame 073824/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2025
From: GYROSCOPE THERAPEUTICS LIMITED
To: NOVARTIS PHARMACEUTICALS UK LIMITED
Reel/Frame 072639/0145 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 056628 FRAME: 0111. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 1, 2021
From: JOEL, JOSEPHINE HEATHER LUCIENNE
To: GYROSCOPE THERAPEUTICS LIMITED
Reel/Frame 056751/0020 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2021
From: JOEL, JOSEPHINE HEATHER LUCIENNE
To: GYROSCOPE THERAPEUTICS LIMITED
Reel/Frame 056628/0111 →
Priority Claims (1)
GB 1821089 · Dec 21, 2018 · national
Continuity (1)
Related Publication 20220073576A1 · Mar 10, 2022
References Cited (81)
US 7745389B2 · Hageman · 2010 [cited by examiner]
US 9066941B2 · Lachmann · 2015 [cited by applicant]
US 9782460B2 · Lachmann · 2017 [cited by applicant]
US 10940186B2 · Lachmann · 2021 [cited by applicant]
US 20130302409A1 · Fuchs et al. · 2013 [cited by applicant]
US 20140271603A1 · Abache · 2014 [cited by applicant]
US 20170190753A1 · Abache · 2017 [cited by applicant]
US 20190255193A1 · Groendahl et al. · 2019 [cited by applicant]
US 20200147240A1 · Lachmann et al. · 2020 [cited by applicant]
US 20210268076A1 · Lachmann · 2021 [cited by applicant]
US 20220072157A1 · Dreismann et al. · 2022 [cited by applicant]
US 20230212275A1 · Joel et al. · 2023 [cited by applicant]
US 20230212635A1 · Marchbank et al. · 2023 [cited by applicant]
US 20230277689A1 · Groendahl et al. · 2023 [cited by applicant]
US 20240238446A1 · Lachmann et al. · 2024 [cited by applicant]
CN 101160412A · 2008 [cited by applicant]
KR 20090122465A · 2009 [cited by applicant]
RU 2473563C2 · 2013 [cited by applicant]
WO WO2006088950A2 · 2006 [cited by applicant]
WO 2007149567A2 · 2007 [cited by applicant]
WO WO2008106644A2 · 2008 [cited by applicant]
WO 2008154251A2 · 2008 [cited by applicant]
WO 2013151665A2 · 2013 [cited by applicant]
WO 2013151666A2 · 2013 [cited by applicant]
WO WO2015092335A2 · 2015 [cited by applicant]
WO 2015130826A1 · 2015 [cited by applicant]
WO WO2016170176A1 · 2016 [cited by applicant]
WO WO2017072515A1 · 2017 [cited by applicant]
WO 2017191274A2 · 2017 [cited by applicant]
WO WO2017194912A1 · 2017 [cited by applicant]
WO WO2018170152A1 · 2018 [cited by applicant]
WO WO2019079718A1 · 2019 [cited by applicant]
Chin, J. X., Chung, B. K. S., & Lee, D. Y. (2014). Codon Optimization OnLine (COOL): a web-based multi-objective optimization platform for synthetic gene design. Bioinformatics, 30(15), 2210-2212. (Year: 2014). [cited by examiner]
Jha et al., 2007, “The role of complement system in ocular diseases including uveitis and macular degeneration,” Mol Immunol 44(16):3901-3908. [cited by applicant]
“Complement factor I isoform 2 preproprotein [ [cited by applicant]
“ [cited by applicant]
“JP 2015516143-A/112869: Modified Polynucleotides for the Production of Proteins Associated With Human Disease,” Database EMBL [Online], EBI accession No. EM PAT:LF518498, Oct. 29, 2016, XP002798767, 2 pages total. [cited by applicant]
“Therapeutic protein CFI codon optimized RNA SEQ:28198,” DATABASE Genseq [Online], EBI Accession No. GS NUC:BFB51614, Apr. 5, 2018, XP002798768, 2 pages total. [cited by applicant]
“Therapeutic protein CFI codon optimized RNA SEQ:41255,” DATABASE Genseq [Online],EBI accession No. GS NUC:BFB64671, Apr. 5, 2018, XP002798769, 2 pages total. [cited by applicant]
Clark et al., “Role of Factor H and Related Proteins in Regulating Complement Activation in the Macula, and Relevance to Age-Related Macular Degeneration,” Journal of Clinical Medicine, vol. 4, Published Dec. 26, 2014, … [cited by applicant]
Allocca et al., 2007, “Novel Adeno-Associated Virus Serotypes Efficiently Tranduce Murine Photoreceptors,” J. Virol. 81:11372-80. [cited by applicant]
Altschul et al., 1990, “Basic local alignment search tool,” J Mol Biol 215(3):403-410. [cited by applicant]
Ausubel et al., 1995, “Current Protocols in Molecular Biology,” John Wiley & Sons. [cited by applicant]
Bainbridge et al., 2008, “Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis,” N. Engl. J. Med. 358: 2231-2239. [cited by applicant]
Booij et al., 2010, “A new strategy to identify and annotate human RPE-specific gene expression,” PLOS ONE 5(5):9341. [cited by applicant]
Bressler et al., 1999, “Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration with Verteporfin,” Arch Ophthalmol 117: 1329-1345. [cited by applicant]
Brown et al., 2006 “Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration,” N Engl J Med 355:1432-1444. [cited by applicant]
Cashman et al., 2015, “Adenovirus-mediated delivery of Factor H attenuates complement C3 induced pathology in the murine retina: a potential gene therapy for age-related macular degeneration,” J. Gene Medicine 17:229-24… [cited by applicant]
Choi et al., 2005, “AAV Hybrid Serotypes: Improved Vectors for Gene Delivery,” Current Gene Therapy 5(3):299-310. [cited by applicant]
Choi et al., 2014, “Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons,” Molecular Brain 7:17. [cited by applicant]
Clark et al., 2015, “Role of Factor H and Related Proteins I Regulating Complement Activation in the Macula, and Relevance to Age-Related Macular Degeneration,” J Clin Med 4:18-31. [cited by applicant]
Degn et al., 2011, “Disease-causing mutations in genes of the complement system,” Am J Hum Genet 88:689-705. [cited by applicant]
Devereux et al., 1984, “A comprehensive set of sequence analysis programs for the VAX,” Nucleic Acids Res 12(1 Part 1):387-395. [cited by applicant]
Dong et al., 1996, “Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus,” Human Gene Therapy 7(17):2101-2112. [cited by applicant]
Dos Santos and Nardi, 2007, “The state of the art of adeno-associated virus-based vectors in gene therapy,” Virology Journal 4: 99. [cited by applicant]
Esumi et al., 2004, “Analysis of the VMD2 Promoter and Implication of E-box Binding Factors in Its Regulation,” J. Biol. Chem. 279:19064-19073. [cited by applicant]
Gait, 1984, “Oligonucleotide Synthesis: A Practical Approach,” IRL Press. [cited by applicant]
Goldberger et al., 1987, “Human Complement Factor I: Analysis of cDNA-derived Primary Structure and Assignment of its Gene to Chromosome 4,” J Biol. Chem. 262(21):10065-10071. [cited by applicant]
Gragoudas et al., 2004, “Pegaptanib for Neovascular Age-Related Macular Degeneration,” N Engl J Med 351: 2805-2816. [cited by applicant]
Harrison, 1996, “Purification, Assay, and Characterization of Complement Proteins from Plasma,” in Herzenberg L A & Weir D M (eds), Weir's Handbook of Experimental Immunology 5(75): 36-37. [cited by applicant]
Hsiung L-M et al., 1982, “Purification of human C3b inactivator by monoclonal-antibody affinity chromatography,” Biochem J. 203:293-298. [cited by applicant]
Kavanagh et al., 2015, “Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels,” Human Mol Genet 24:3861-3870. [cited by applicant]
Lachmann, 2009, “The amplification loop of the complement pathways,” Adv. Immunol. 104:115-149. [cited by applicant]
Lachmann & Hobart, 1978, “Handbook of Experimental Immunology,” chapter 5A in “Complement Technology”, 17 pages. [cited by applicant]
Laughlin et al., 1979, “Spliced adenovirus-associated virus RNA,” Proc. Natl. Acad. Sci. 76(11):5567-5571. [cited by applicant]
Lilley et al., 1992, Methods in Enzymology, vol. 211, DNA Structures, Part A “Synthesis and Physical Analysis of DNA”, Academic Press. [cited by applicant]
Mancuso et al., 2009, “Gene therapy for red-green colour blindness in adult primates,” Nature 461(7265):784-787. [cited by applicant]
Nilsson et al., 2011, “Complement factor I in health and disease,” Molecular Immunology 48:1611-1620. [cited by applicant]
Polak, 1990, “Situ Hybridization: Principles and Practice,” Oxford University Press. [cited by applicant]
Roe et al., 1996, “DNA Isolation and Sequencing: Essential Techniques,” John Wiley & Sons. [cited by applicant]
Roversi et al., 2011, “Structural basis for complement factor I control and its disease- associated sequence polymorphisms,” Proc Nat Acad Sci 108:12839-12844. [cited by applicant]
Sambrook and Maniatis, 1989, “Molecular Cloning: A Laboratory Manual,” Cold Spring Harbor Laboratory Press. [cited by applicant]
Schmidt et al., 2008, “A New Map of Glycosaminoglycan and C3b Binding Sites on Factor H,” Journal of Immunology 181:2610-2619. [cited by applicant]
Seddon, 2001, “Epidemiology of age-related macular degeneration,”.in Ogden, T.E., et al., eds. Ryan S.J., ed-in-chief. Retina vol. II. 3rd ed. St. Louis, Mo.: Mosby; 2001: 1039-1050. [cited by applicant]
Tatusova et al., 1999, “BLAST 2 SEQUENCES, a new tool for comparing protein and nucleotide sequences,” FEMS Microbiology Letters 174(2):247-250. [cited by applicant]
Tufail et al., 2010, “Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study,” BMJ 340: c2459. [cited by applicant]
“UniProtKB,” Database accession No. P08603, Jan. 16, 2019. [cited by applicant]
Wu et al., 2006, “Adeno-associated virus serotypes: vector toolkit for human gene therapy,” Molecular Therapy 14:316-27. [cited by applicant]
Hallam, et al, 2024, “Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degeneration,” eLife 13:RP99806. [cited by applicant]
UniProtKB—P05156 (CFAI_HUMAN), Accession No. P05616, accessed from uniprot.org/uniprotkb/P05156/entry on Dec. 20, 2024. [cited by applicant]
Ahmad et al., 2018, “P135: Reduced activity of the complement system through elevation of complement factor I using AAV mediated gene delivery to the liver,” Human Gene Therapy 29(12):A67 (poster presentation abstract, … [cited by applicant]